Status:
COMPLETED
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
Lead Sponsor:
Forest Laboratories
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. ...
Eligibility Criteria
Inclusion
- DSM-IV diagnosed Schizophrenia or schizoaffective disorder who are on a stable antipsychotic regimen with Brief Psychiatric Rating Scale (BPRS) total score greater than or equal to 26 and greater than or equal to 4 on at least one item
Exclusion
- Secondary diagnosis of Bipolar I disorder
- Suicidal history
- Organic brain disease
- Dementia
- History of substance abuse
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00097942
Start Date
August 1 2004
End Date
September 1 2005
Last Update
March 5 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Synergy Clinical Research
National City, California, United States, 91950
2
VA San Diego Healthcare System
San Diego, California, United States, 92161
3
University of Miami Jackson Memorial Hospital
Miami, Florida, United States, 33136
4
University of Iowa Psychiatric Research
Iowa City, Iowa, United States, 52242